1,758 reports of this reaction
3.7% of all IMATINIB MESYLATE reports
#3 most reported adverse reaction
DIARRHOEA is the #3 most commonly reported adverse reaction for IMATINIB MESYLATE, manufactured by Novartis Pharmaceuticals Corporation. There are 1,758 FDA adverse event reports linking IMATINIB MESYLATE to DIARRHOEA. This represents approximately 3.7% of all 47,520 adverse event reports for this drug.
Patients taking IMATINIB MESYLATE who experience diarrhoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIARRHOEA is moderately reported among IMATINIB MESYLATE users, representing a notable but not dominant share of adverse events.
In addition to diarrhoea, the following adverse reactions have been reported for IMATINIB MESYLATE:
The following drugs have also been linked to diarrhoea in FDA adverse event reports:
DIARRHOEA has been reported as an adverse event in 1,758 FDA reports for IMATINIB MESYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIARRHOEA accounts for approximately 3.7% of all adverse event reports for IMATINIB MESYLATE, making it one of the most commonly reported side effect.
If you experience diarrhoea while taking IMATINIB MESYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.